

F. LUPUS ERYTHEMATOSUS

1. Cameron JS, Boulton-Jones M, Robinson R, Ogg C. Treatment of lupus nephritis with cyclophosphamide. *Lancet*. 1970 Oct;2(7678):846-9.
2. Cameron JS, Jones MB. Lupus nephritis: long-term follow-up. *Perspect Nephrol Hypertens*. 1973;1 Pt 2(0):1187-91.
3. Sanderson C, Williams BD, Cameron JS. Letter: Precipitating antibodies in systemic lupus. *Lancet*. 1974 Apr;1(7859):677-8.
4. Cameron JS, Lessof MH, Ogg CS, Williams BD, Williams DG. Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations. DNA-binding capacity and precipitating anti-DNA antibody. *Clin Exp Immunol*. 1976 Sep;25(3):418-27.
5. Slater NG, Cameron JS, Lessof MH. The Crithidia luciliae kinetoplast immunofluorescence test in systemic lupus erythematosus. *Clin Exp Immunol*. 1976 Sep;25(3):480-6.
6. Levinsky RJ, Cameron JS, Soothill JF. Serum immune complexes and disease activity in lupus nephritis. *Lancet*. 1977 Mar;1(8011):564-7.
7. Cameron JS, Turner DR, Vosnides G, Leibowitz S, Lessof MH, Ogg CS, Chantler C, Brown CB. The kidney in systemic lupus erythematosus. *Perspect Nephrol Hypertens*. 1977;6:41-81.
8. Cameron JS, Turner DR, Ogg CS, Williams DG, Lessof MH, Chantler C, Leibowitz S. Systemic lupus with nephritis: a long-term study. *Q J Med*. 1979;48(189):1-24.
9. Parbtani A, Frampton G, Yewdall V, Kasai N, Cameron JS. Platelet and plasma serotonin in glomerulonephritis. III: The nephritis of systemic lupus erythematosus. *Clin Nephrol*. 1980;14(4):164-72.
10. Marchesi D, Parbtani A, Frampton G, Livio M, Remuzzi G, Cameron JS. Thrombotic tendency in systemic lupus erythematosus. *Lancet*. 1981 Mar;1(8222):719.
11. Morris MC, Cameron JS, Chantler C, Turner DR. Systemic lupus erythematosus with nephritis. *Arch Dis Child*. 1981 Oct;56(10):779-83.
12. Adu D, Cameron JS. Lupus Nephritis. *Clin Rheum Dis*. 1982 Apr;8(1):153-82.
13. Hughes RA, Cameron JS, Hall SM, Heaton J, Payan J, Teoh R. Multiple mononeuropathy as the initial presentation of systemic lupus erythematosus--nerve biopsy and response to plasma exchange. *J Neurol*. 1982;228(4):239-47.
14. Yewdall V, Cameron JS, Nathan AW, Neild G, Ogg CS, Williams DG. Systemic lupus erythematosus and IgA deficiency. *J Clin Lab Immunol*. 1983 Jan;10(1):13-8.
15. Adu D, Williams DG, Taube D, Vilches AR, Turner DR, Cameron JS, Ogg CS. Late onset systemic lupus erythematosus and lupus-like disease in patients with apparent idiopathic glomerulonephritis. *Q J Med*. 1983 Autumn;52(208):471-87.
16. Correia P, Cameron JS, Ogg CS, Williams DG, Bewick M, Hicks JA. End-stage renal failure in systemic lupus erythematosus with nephritis. *Clin Nephrol*. 1984 Dec;22(6):293-302.
17. Correia P, Cameron JS, Lian JD, Hicks J, Ogg CS, Williams DG, Chantler C, Haycock DG. Why do patients with lupus nephritis die? *Br Med J (Clin Res Ed)* 1985 Jan;290(6462):126-31.
18. Frampton G, Perl S, Bennett A, Cameron JS. Platelet-associated DNA and anti-DNA antibody in systemic lupus erythematosus with nephritis. *Clin Exp Immunol*. 1986 Mar;63(3):621-8.
19. Bennett A, Frampton G, Cameron JS. Platelet-associated IgG in idiopathic glomerulonephritis and the nephritis of systemic lupus erythematosus. *Br J Haematol*. 1986 Apr;62(4):695-703.
20. Frampton G, Cameron JS, Thom M, Jones S, Raftery M. Successful removal of anti-phospholipid antibody during pregnancy using plasma exchange and low-dose prednisolone. *Lancet*. 1987 Oct;2(8566):1023-4.

21. Frampton G, Hildreth G, Hartley B, Cameron JS, Heldin CH, Wasteson A. Could platelet-derived growth factor have a role in the pathogenesis of lupus nephritis? *Lancet*. 1988 Aug;2(8606):343.
22. Cameron JS. The treatment of lupus nephritis. *Pediatr Nephrol*. 1989 Jul;3(3):350-62.
23. Alexopoulos E, Seron D, Hartley RB, Cameron JS. Lupus nephritis: correlation of interstitial cells with glomerular function. *Kidney Int*. 1990 Jan;37(1):100-9.
24. Cameron JS. When a patient with known lupus nephritis has persistent proteinuria despite corticosteroids and immunosuppressive treatment can it be assumed that there is continuing disease activity or may it reflect irreparable glomerular damage? How can one be sure? *Br J Rheumatol*. 1990 Feb;29(1):68.
25. Cameron JS, Frampton G. The 'antiphospholipid syndrome' and the 'lupus anticoagulant'. *Pediatr Nephrol*. 1990 Nov;4(6):663-78.
26. Chan TM, Frampton G, Staines NA, Hobby P, Perry GJ, Cameron JS. Different mechanisms by which anti-DNA MoAbs bind to human endothelial cells and glomerular mesangial cells. *Clin Exp Immunol*. 1992 Apr;88(1):68-74.
27. Cameron JS. Pathogenesis and treatment of lupus nephritis. *Nihon Jinzo Gakkai Shi*. 1991 May;33(5):443-6.
28. Frampton G, Hobby P, Morgan A, Staines NA, Cameron JS. A role for DNA in anti-DNA antibodies binding to endothelial cells. *J Autoimmun*. 1991 Jun;4(3):463-78.
29. Frampton G, Hicks J, Cameron JS. Significance of anti-phospholipid antibodies in patients with lupus nephritis. *Kidney Int*. 1991 Jun;39(6):1225-31.
30. Oviasu E, Hicks J, Cameron JS. The outcome of pregnancy in women with lupus nephritis. *Lupus*. 1991 Nov;1(1):19-25.
31. Cameron JS. Prediction of outcome in lupus nephritis. *Lupus*. 1992 Aug;1(4):197.
32. Frampton G, Perry GJ, Chan TM, Cameron JS. Significance of anticardiolipin and antiendothelial cell antibodies in the nephritis of lupus. *Contrib Nephrol*. 1992;99:7-16.
33. Chan TM, Frampton G, Cameron JS. Identification of DNA-binding proteins on human umbilical vein endothelial cell plasma membrane. *Clin Exp Immunol*. 1993 Jan;91(1):110-4.
34. Chan TM, Frampton G, Jayne DR, Perry GJ, Lockwood CM, Cameron JS. Clinical significance of anti-endothelial cell antibodies in systemic vasculitis: a longitudinal study comparing anti-endothelial cell antibodies and anti-neutrophil cytoplasm antibodies. *Am J Kidney Dis*. 1993 Sept;22(3):387-92.
35. Andrews PA, Frampton G, Cameron JS. Antiphospholipid syndrome and systemic lupus erythematosus. *Lancet*. 1993 Oct;342(8877):988-9.
36. Perry GJ, Elston T, Khouri NA, Chan TM, Cameron JS, Frampton G. Anti-endothelial cell antibodies in lupus: correlations with renal injury and circulating markers of endothelial damage. *Q J Med*. 1993 Nov;86(11):727-34.
37. Cameron JS. Lupus and lupus nephritis in children. *Adv Nephrol Necker Hosp*. 1993;22:59-119.
38. Cameron JS. Lupus nephritis in childhood and adolescence. *Pediatr Nephrol*. 1994 Apr;8(2):230-49.
39. Cameron JS. Lupus nephritis. *J Am Soc Nephrol*. 1999 Feb;10(2):413-24.
40. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. *Q J Med*. 1999 Apr;92(4):211-8.
41. Cameron JS. Lupus nephritis: an historical perspective 1968-1998. *J Nephrol*. 1999 Jul-Aug;12 Suppl 2:S29-41.